NEW YORK (GenomeWeb News) – Pacific Biometrics said today that it has been awarded two contracts worth a total of $1.6 million from an unnamed company to provide clinical services for use in rheumatoid arthritis drug development programs.
 
The Seattle-based firm said the contracts are part of a series of four contracts related to a global development program. PBI will offer testing for a panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support its partner’s phase III clinical program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.